Edesa Biotech Files 8-K: Corporate Updates
Ticker: EDSA · Form: 8-K · Filed: Sep 9, 2025 · CIK: 1540159
| Field | Detail |
|---|---|
| Company | Edesa Biotech, Inc. (EDSA) |
| Form Type | 8-K |
| Filed Date | Sep 9, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $4,006,544, $837,134 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-update, filing
Related Tickers: EDSA
TL;DR
Edesa Biotech (EDSA) filed an 8-K on 9/9/25. No major news, just corporate housekeeping.
AI Summary
Edesa Biotech, Inc. filed an 8-K on September 9, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing indicates the company's principal executive offices are located at 100 Spy Court, Markham, Ontario, Canada, L3R 5H6, with a contact phone number of (289) 800-9600. The company was formerly known as Stellar Biotechnologies, Inc., with a name change effective January 20, 2012.
Why It Matters
This 8-K filing provides an update on Edesa Biotech's corporate structure and reporting, which is important for investors to stay informed about the company's official disclosures.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for corporate information and does not appear to contain significant new financial or operational developments.
Key Players & Entities
- Edesa Biotech, Inc. (company) — Registrant
- September 9, 2025 (date) — Date of earliest event reported
- 100 Spy Court, Markham, Ontario, Canada L3R 5H6 (location) — Address of Principal Executive Offices
- (289) 800-9600 (phone_number) — Registrant's telephone number
- Stellar Biotechnologies, Inc. (company) — Former company name
- 20120120 (date) — Date of former company name change
FAQ
What is the primary purpose of this 8-K filing for Edesa Biotech, Inc.?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of September 9, 2025.
Where are Edesa Biotech, Inc.'s principal executive offices located?
Edesa Biotech, Inc.'s principal executive offices are located at 100 Spy Court, Markham, Ontario, Canada L3R 5H6.
What was Edesa Biotech, Inc.'s former company name?
Edesa Biotech, Inc.'s former company name was Stellar Biotechnologies, Inc.
When was the name change from Stellar Biotechnologies, Inc. to Edesa Biotech, Inc. effective?
The name change from Stellar Biotechnologies, Inc. was effective on January 20, 2012.
What is the telephone number for Edesa Biotech, Inc.'s principal executive offices?
The telephone number for Edesa Biotech, Inc.'s principal executive offices is (289) 800-9600.
Filing Stats: 740 words · 3 min read · ~2 pages · Grade level 12 · Accepted 2025-09-09 16:35:29
Key Financial Figures
- $4,006,544 — program for the offer and sale of up to $4,006,544 of the Company's common shares, without
- $837,134 — f, the Company has sold an aggregate of $837,134 of Common Shares pursuant to the ATM Ag
Filing Documents
- f8k_090925.htm (8-K) — 24KB
- exh_51.htm (EX-5.1) — 14KB
- faskenheader.jpg (GRAPHIC) — 17KB
- footer.jpg (GRAPHIC) — 1KB
- fasken.jpg (GRAPHIC) — 3KB
- 0001171843-25-005800.txt ( ) — 231KB
- edsa-20250829.xsd (EX-101.SCH) — 3KB
- edsa-20250829_lab.xml (EX-101.LAB) — 33KB
- edsa-20250829_pre.xml (EX-101.PRE) — 22KB
- f8k_090925_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On September 9, 2025, Edesa Biotech, Inc. (the "Company"), filed a prospectus supplement (the "Prospectus Supplement") with the U.S. Securities and Exchange Commission (the "SEC") in connection with the Company's "at the market offering" program for the offer and sale of up to $4,006,544 of the Company's common shares, without par value (the "Common Shares"), from time to time through H.C. Wainwright & Co., LLC ("Wainwright"), as sales agent, pursuant to the Company's existing At the Market Offering Agreement (the "ATM Agreement"), dated October 4, 2024. As of the date hereof, the Company has sold an aggregate of $837,134 of Common Shares pursuant to the ATM Agreement and the related prospectus supplement, dated October 4, 2024 to the Company's Registration Statement on Form S-3 (333-266604). The offer and sale of additional Common Shares by the Company under the ATM Agreement will be made pursuant to the Prospectus Supplement, dated September 9, 2025, and the accompanying base prospectus, dated September 9, 2025, contained therein, which together form a part of the Company's shelf registration statement on Form S-3 (File No. 333-288966), initially filed with the SEC on July 25, 2025 and declared effective by the SEC on September 9, 2025 (the "Registration Statement"). Fasken Martineau DuMoulin LLP, counsel to the Company, has issued a legal opinion relating to the validity of the $4,006,544 Common Shares that may be offered and sold pursuant to the ATM Agreement and related Prospectus Supplement. A copy of such legal opinion, including the consent included therein, is attached as Exhibit 5.1 to this Current Report on Form 8-K. This Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy the Common Shares discussed herein, nor shall there be any sale of such securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualific
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits The following exhibits are furnished with this Current Report on Form 8-K: Exhibit Number Exhibit Description 5.1 Opinion of Fasken Martineau DuMoulin LLP 23.1 Consent of Fasken Martineau DuMoulin LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within in the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Edesa Biotech, Inc. Date: September 9, 2025 By: /s/ Peter Weiler Name: Peter Weiler Title: Chief Financial Officer